Issue 2026-11-17 · Industry · 政策

FDA to refer to AI as 'super intelligence' going forward

FDA to refer to AI as 'super intelligence' going forward

The US FDA will refer to artificial intelligence as 'super intelligence' going forward, RAPS reported. The same briefing noted FDA approval of Roche's oral SERD for late-stage breast cancer and Lilly's cancer deal with Stipple Bio worth up to $5.9 billion.

RAPS16 h ago
Read original ↗